BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2021 12:47:36 PM | Browse: 408 | Download: 752
 |
Received |
|
2020-09-27 17:27 |
|
Peer-Review Started |
|
2020-09-27 17:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-01-07 06:20 |
|
Revised |
|
2021-01-07 15:24 |
|
Second Decision |
|
2021-01-21 03:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-01-26 18:31 |
|
Articles in Press |
|
2021-01-26 18:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-01-29 23:27 |
|
Typeset the Manuscript |
|
2021-02-01 05:32 |
|
Publish the Manuscript Online |
|
2021-02-22 12:47 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Metastatic hormone-sensitive prostate cancer: How should it be treated?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Fernando López-Campos, Carmen González-San Segundo, Antonio José Conde-Moreno and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Felipe Couñago, MD, PhD, Professor, Department of Radiation Oncology, Hospital Universitario Quirón Salud Madrid, Hospital La Luz, Universidad Europea de Madrid (UEM), Calle Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Madrid 28223, Spain. fcounago@gmail.com |
| Key Words |
Metastatic hormone-sensitive prostate cancer; Androgen-receptor signaling inhibitors; Abiraterone acetate; Enzalutamide; Apalutamide; Docetaxel |
| Core Tip |
Due to advances in the treatment of metastatic hormone-sensitive prostate cancer in recent years, multiple options are now available. The emergence of androgen receptor inhibitors provides patients with an alternative to chemotherapy. Given the increasingly important role of these novel treatments, a comprehensive review of the available data is needed. In addition, there are several unresolved questions and controversies surrounding these treatments, which can only be resolved by in-depth analysis and consensus among the specialists who treat these patients. |
| Publish Date |
2021-02-22 12:47 |
| Citation |
López-Campos F, González-San Segundo C, Conde-Moreno AJ, Couñago F. Metastatic hormone-sensitive prostate cancer: How should it be treated? World J Clin Oncol 2021; 12(2): 43-49 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i2/43.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i2.43 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
